Table 3.
Evaluation characteristics of norfloxacin nanoparticles
| Formulation code |
Particle size
(nm) |
PDI | Zeta potential (mV) |
pH
(± SD) |
% Entrapment efficiency
(±SD) |
%CDR at 1h (±SD) |
% CDR
at 12h (± SD) |
|
|---|---|---|---|---|---|---|---|---|
| N1 | 158.4 | 0.270 | +38 | 6.04 ±0.02 | 64.77 ± 0.37 | 46.35±1.09 | 94.49 ± 0.69 | |
| N2 | 192.8 | 0.324 | +31 | 6.09± 0.01 | 68.27 ± 0.18 | 43.81±0.74 | 91.37 ± 0.50 | |
| N3 | 345.8 | 0.470 | +28 | 5.92 ±0.03 | 68.95 ± 0.49 | 32.34±0.60 | 82.61. ± 0.87 | |
| N4 | 164.2 | 0.071 | +32 | 5.85 ±0.01 | 74.51 ± 0.33 | 45.37±1.27 | 95.74 ± 0.92 | |
| N5 | 215.6 | 0.120 | +42 | 5.94± 0.03 | 76.42 ± .21 | 42.24±1.27 | 93.11 ± 0.36 | |
| N6 | 243.8 | 0.181 | +39 | 6.1 ± 0.02 | 77.38 ± 0.29 | 37.65±0.67 | 90.30 ± 0.43 | |
| N7 | 256.1 | 0.210 | +46 | 6.05± 0.02 | 70.17 ± 0.46 | 38.80±1.21 | 92.18 ± 0.19 | |
| N8 | 298.4 | 0.180 | +41 | 6.18 ±0.03 | 71.88 ± 0.87 | 36.75±0.89 | 89.63 ± 0.36 | |
| N9 | 310.6 | 0.235 | +39 | 6.21± 0.13 | 73.21 ± 0.26 | 33.31±0.40 | 86.54 ± 1.52 | |
| N10* | 164.6 | 0.112 | +37 | 6.13 ±0.11 | 72.65 ±0.87 | 40.55±0.68 | 91.23 ± 1.48 | |
*
Extra design check point